Literature DB >> 26223500

Genetic deletion of monoacylglycerol lipase leads to impaired cannabinoid receptor CB₁R signaling and anxiety-like behavior.

Roberta Imperatore1, Giovanna Morello1,2, Livio Luongo3, Ulrike Taschler4, Rosaria Romano3, Danilo De Gregorio3, Carmela Belardo3, Sabatino Maione3, Vincenzo Di Marzo1, Luigia Cristino1.   

Abstract

Endocannabinoids (eCB) are key regulators of excitatory/inhibitory neurotransmission at cannabinoid-1-receptor (CB1 R)-expressing axon terminals. The most abundant eCB in the brain, that is 2-arachidonoylglycerol (2-AG), is hydrolyzed by the enzyme monoacylglycerol lipase (MAGL), whose chronic inhibition in the brain was reported to cause CB1 R desensitization. We employed the MAGL knock-out mouse (MAGL-/-), a genetic model of congenital and sustained elevation of 2-AG levels in the brain, to provide morphological and biochemical evidence for β-arrestin2-mediated CB1 R desensitization in brain regions involved in the control of emotional states, that is, the prefrontal cortex (PFC), amygdala, hippocampus and cerebellar cortex. We found a widespread CB1 R/β-arrestin2 co-expression in the mPFC, amygdala and hippocampus accompanied by impairment of extracellular signal-regulated kinase signaling and elevation of vesicular glutamate transporter (VGluT1) at CB1 R-positive excitatory terminals in the mPFC, or vesicular GABA transporter (VGAT) at CB1 R-positive inhibitory terminals in the amygdala and hippocampus. The impairment of CB1 R signaling in MAGL-/- mice was also accompanied by enhanced excitatory drive in the basolateral amygdala (BLA)-mPFC circuit, with subsequent elevation of glutamate release to the mPFC and anxiety-like and obsessive-compulsive behaviors, as assessed by the light/dark box and marble burying tests, respectively. Collectively, these data provide evidence for a β-arrestin2-mediated desensitization of CB1 R in MAGL-/- mice, with impact on the synaptic plasticity of brain circuits involved in emotional functions. In this study, the authors provide evidence that congenitally enhanced endocannabinoid levels in the neuronal circuits underlying anxiety-like behavioral states (mainly medial prefrontal cortex, amygdala and hippocampus) lead to CB1R desenistization and anxiety and depression. MAGL-/- mice, a model of congenital overactivity of the eCB system, exhibited a compensatory impairment of CB1R signaling in anxiety-associated brain areas and a subsequent change in excitatory/inhibitory tone associated with altered score in the marble burying and light/dark box test, in concomitance with anxiety and depression behavior states. These findings may have potential relevance to the understanding of the neurochemical effects of chronic CB1R overstimulation in cannabis abusers.
© 2015 International Society for Neurochemistry.

Entities:  

Keywords:  2-arachidonoylglycerol (2-AG); CB1R; MAGL-KO mice; anxiety-like behavior; endocannabinoids; synaptic plasticity

Mesh:

Substances:

Year:  2015        PMID: 26223500     DOI: 10.1111/jnc.13267

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  21 in total

1.  Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats.

Authors:  Marek Zubrzycki; Anna Janecka; Andreas Liebold; Mechthild Ziegler; Maria Zubrzycka
Journal:  Br J Pharmacol       Date:  2017-08-30       Impact factor: 8.739

2.  Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.

Authors:  S Tai; W S Hyatt; C Gu; L N Franks; T Vasiljevik; L K Brents; P L Prather; W E Fantegrossi
Journal:  Pharmacol Res       Date:  2015-09-08       Impact factor: 7.658

Review 3.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

Review 4.  Cannabinoids in the descending pain modulatory circuit: Role in inflammation.

Authors:  Courtney A Bouchet; Susan L Ingram
Journal:  Pharmacol Ther       Date:  2020-01-29       Impact factor: 12.310

5.  Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain.

Authors:  Emma Leishman; Ben Cornett; Karl Spork; Alex Straiker; Ken Mackie; Heather B Bradshaw
Journal:  Pharmacol Res       Date:  2016-04-22       Impact factor: 7.658

Review 6.  The cannabinoid system and pain.

Authors:  Stephen G Woodhams; Victoria Chapman; David P Finn; Andrea G Hohmann; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

Review 7.  Synaptic functions of endocannabinoid signaling in health and disease.

Authors:  Alfonso Araque; Pablo E Castillo; Olivier J Manzoni; Raffaella Tonini
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

Review 8.  Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling.

Authors:  Gernot F Grabner; Robert Zimmermann; Rudolf Schicho; Ulrike Taschler
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

Review 9.  Developmental regulation of fear learning and anxiety behavior by endocannabinoids.

Authors:  T T-Y Lee; M N Hill; F S Lee
Journal:  Genes Brain Behav       Date:  2015-11-05       Impact factor: 3.449

Review 10.  Druggable Targets in Endocannabinoid Signaling.

Authors:  Ann M Gregus; Matthew W Buczynski
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.